S Kuwabara
Overview
Explore the profile of S Kuwabara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
276
Citations
2069
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kristensen A, Gylfadottir S, Itani M, Kuwabara S, Kroigard T, Khan K, et al.
Clin Neurophysiol
. 2021 May;
132(7):1407-1415.
PMID: 34030050
Objective: The aim of the present study was to gain insight into the pathophysiology of diabetic polyneuropathy (DPN) and examine the diagnostic value of sensory and motor axonal excitability testing....
2.
Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y, et al.
Clin Exp Immunol
. 2020 Nov;
203(3):366-374.
PMID: 33184844
Myasthenia gravis (MG) is characterized by muscle weakness and fatigue caused by the presence of autoantibodies against the acetylcholine receptor (AChR) or the muscle-specific tyrosine kinase (MuSK). Activated T, B...
3.
Ozawa Y, Uzawa A, Yasuda M, Kojima Y, Oda F, Himuro K, et al.
Eur J Neurol
. 2020 Sep;
28(1):314-322.
PMID: 32889770
Objective: To investigate changes in serum complements and their regulators in the pathogenesis of myasthenia gravis (MG). Methods: Forty-four patients with acetylcholine receptor antibody-positive MG, as well as 20 patients...
4.
Shibuya K, Tsuneyama A, Misawa S, Suichi T, Suzuki Y, Kojima Y, et al.
Eur J Neurol
. 2020 Sep;
27(12):2658-2661.
PMID: 32876980
Background And Purpose: Cranial nerve palsy is occasionally present in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), but its prevalence, characteristics and relations with the CIDP subtypes have rarely been...
5.
Uzawa A, Kojima Y, Ozawa Y, Yasuda M, Onishi Y, Akamine H, et al.
Clin Exp Immunol
. 2020 Jul;
202(3):321-324.
PMID: 32706905
Myasthenia gravis (MG) is an autoantibody-mediated inflammatory disease of the neuromuscular junction. Biomarkers indicating disease activity in MG are warranted. Recently, the soluble urokinase plasminogen activator receptor (suPAR) has been...
6.
Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Aoki R, et al.
Clin Exp Immunol
. 2020 Jul;
202(2):239-248.
PMID: 32643149
Peroxiredoxins (PRXs) are intracellular anti-oxidative enzymes but work as inflammatory amplifiers under the extracellular condition. To date, the function of PRXs in the pathogenesis of multiple sclerosis (MS) and neuromyelitis...
7.
Masuda H, Mori M, Hirano S, Uzawa A, Uchida T, Ohtani R, et al.
Eur J Neurol
. 2020 May;
27(10):2056-2061.
PMID: 32427379
Background And Purpose: The silent progression of patients with multiple sclerosis (MS) has been reported. The aim of this study was to investigate the association between brain atrophy rates and...
8.
Uzawa A, Kanai T, Oda F, Ozawa Y, Yasuda M, Kawaguchi N, et al.
Eur J Neurol
. 2019 Jul;
27(1):175-180.
PMID: 31347231
Background And Purpose: Thymectomy is an effective treatment for myasthenia gravis (MG) with anti-acetylcholine receptor (AChR) antibodies. We rarely encounter patients who develop MG after surgery for thymic tumors. This...
9.
Nishida Y, Takahashi Y, Kanai T, Nose Y, Ishibashi S, Sanjo N, et al.
Eur J Neurol
. 2019 Jul;
27(1):100-104.
PMID: 31309642
Background And Purpose: Tapering immunosuppressants is desirable in patients with well-controlled myasthenia gravis (MG). However, the association between tapering of calcineurin inhibitor dosage and reduction-associated exacerbation is not known. The...
10.
Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Kuwabara S
Clin Exp Immunol
. 2018 Mar;
193(1):47-54.
PMID: 29509323
Recombinant thrombomodulin (rTM) has pleiotrophic properties, including anti-coagulation and anti-inflammation; however, its effectiveness as a treatment for multiple sclerosis (MS) has not been evaluated fully. High mobility group box 1...